Parag Joshi is a Cardiology physician affiliated with The University of Texas Southwestern Medical Center. OpenAlex indexes 239 publications with 5,291 citations (h-index 38); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5323 Harry Hines Blvd
Dallas, TX 753907201
Telephone
214-645-8000Registry record last updated 8 Sept 2015.
Clinical trials
- Impact of Liraglutide 3.0 on Body Fat Distribution
Sponsor: University of Texas Southwestern Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20251 payment
- ABIOMEDProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
89%Statin25.5%Atorvastatin Calcium75%Rosuvastatin Calcium25%Part D≥54 patientsPCSK9 Inhibitor19.4%Repatha Sureclick84%Praluent Pen16%Part D<11 patients+ 10 more classes in this area
Blood & clotting
6.5%Factor Xa inhibitor3.1%Eliquis100%Part D<11 patientsP2Y12 inhibitor1.9%Clopidogrel100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
4.4%SGLT2 inhibitor4.4%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial
Journal of Cachexia Sarcopenia and Muscle
2024 - Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes
American Journal of Preventive Cardiology
2023 - Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk
Journal of the American College of Cardiology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Toto, MD
The University of Texas Southwestern Medical Center
Abhimanyu Garg, MD
The University of Texas Southwestern Medical Center
Jing Chen, MD
The University of Texas Southwestern Medical Center
Raksha Jain, MD
The University of Texas Southwestern Medical Center
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”